Merrimack Pharma stops the Phase 2 HERMIONE study of MM-302 in HER2-positive metastatic breast cancer patients who had previously been treated with trastuzumab, pertuzumab and ado-trastuzumab emtansine:
- The decision to stop the trial was made following the Data and Safety Monitoring Board's opinion that continuing would be unlikely to demonstrate benefit over the comparator treatments. Subsequent to this recommendation, a futility assessment was performed that confirmed the DSMB's opinion. Both the treatment and control arms were found to have shorter than expected median progression free survival.
- Importantly, there were no new or unexpected safety concerns. Patients currently enrolled in the trial may choose to continue on their assigned treatment based upon discussion with their study physician.
- In light of this development, Merrimack now expects to provide further details about MM-302, as well as the results of its full pipeline review, in January.
No comments:
Post a Comment